Three cases of grade 5 ICANS were reported across cohorts, one in a study using a brexucabtagene autoleucel agent in leukemia patients, one in a cohort of multiple myeloma patients using a ciltacabtagene autoleucel agent, and one in leukemia patients using an anti-CD19 agent. The gene discussed is CD19; the disease is leukemia.